Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: a population-based modelling study. EClinicalmedicine. 2022;47:101404.

Article  PubMed  PubMed Central  Google Scholar 

Obama K, Kim YM, Kang DR, et al. Long-term oncologic outcomes of robotic gastrectomy for gastric cancer compared with laparoscopic gastrectomy. Gastric Cancer. 2018;21:285–95.

Article  PubMed  Google Scholar 

Liu D, Lu M, Li J, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016;14:305.

Article  PubMed  PubMed Central  Google Scholar 

Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234–47.

Article  CAS  PubMed  Google Scholar 

Yamaguchi K, Yoshida K, Tanahashi T, et al. The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer. 2018;21:315–23.

Article  CAS  PubMed  Google Scholar 

Arigami T, Matsushita D, Okubo K, et al. Clinical significance of conversion surgery for gastric cancer with peritoneal dissemination: a retrospective study. Oncology. 2020;98:798–806.

Article  PubMed  Google Scholar 

Bigot F, Castanon E, Baldini C, et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017;84:212–8.

Article  CAS  PubMed  Google Scholar 

Nakazawa N, Sohda M, Ubukata Y, et al. Changes in the Gustave Roussy immune score as a powerful prognostic marker of the therapeutic sensitivity of nivolumab in advanced gastric cancer: a multicenter, retrospective study. Ann Surg Oncol. 2022;29:7400–6. https://doi.org/10.1245/s10434-022-12226-4.

Article  PubMed  Google Scholar 

Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111:518–26.

CAS  PubMed  Google Scholar 

Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, Fifteenth Edition. Kanehara Shuppan; 2017.

Liang H, Yan X, Li Z, et al. Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer. Int J Surg. 2023;109:4162–72.

Article  PubMed  PubMed Central  Google Scholar 

Yoshida K, Yasufuku I, Terashima M, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2022;6:227–40.

Article  PubMed  Google Scholar 

Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329–38.

Article  PubMed  Google Scholar 

Hojo Y, Ishida Y, Tomita T, et al. Treatment strategy for successful conversion surgery in clinical stage IVB gastric cancer. Eur J Surg Oncol. 2024;50:107314.

Article  PubMed  Google Scholar 

Chen GM, Yuan SQ, Nie RC, et al. Surgical outcome and long-term survival of conversion surgery for advanced gastric cancer. Ann Surg Oncol. 2020;27:4250–60. https://doi.org/10.1245/s10434-020-08559-7.

Article  PubMed  Google Scholar 

Fukuchi M, Ishiguro T, Ogata K, et al. Prognostic role of conversion surgery for unresectable gastric cancer. Ann Surg Oncol. 2015;22:3618–24. https://doi.org/10.1245/s10434-015-4422-6.

Article  PubMed  Google Scholar 

Sato S, Kunisaki C, Tanaka Y, et al. Curative-intent surgery for stage IV advanced gastric cancer: who can undergo surgery and what are the prognostic factors for long-term survival? Ann Surg Oncol. 2019;26:4452–63. https://doi.org/10.1245/s10434-019-07790-1.

Article  PubMed  Google Scholar 

Yang Z, Lu S, Shi M, et al. Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study. Gastric Cancer. 2024;27:387–99.

Article  CAS  PubMed  Google Scholar 

Lenci E, Cantini L, Pecci F, et al. The Gustave Roussy immune (GRIm)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (NSCLC) patients treated with first-line pembrolizumab. J Clin Med. 2021;10:1005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shangguan J, Huang X, Liu X, et al. Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study. Front Oncol. 2023;13:1195499.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minami S, Ihara S, Ikuta S, Komuta K. Gustave Roussy immune score and Royal Marsden Hospital prognostic score are biomarkers of immune-checkpoint inhibitor for non-small cell lung cancer. World J Oncol. 2019;10:90–100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hatanaka T, Naganuma A, Hiraoka A, et al. The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis. Cancer Med. 2023;12:4259–69.

Article  CAS  PubMed  Google Scholar 

Nie X, Xu T, Zhang L, Cheng W. The Gustave Roussy immune score as a novel scoring system for predicting platinum resistance in advanced high-grade serous ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2024;294:97–104.

Article  PubMed  Google Scholar 

Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71:2411–6.

Article  CAS  PubMed  Google Scholar 

Grimm M, Feyen O, Hofmann H, et al. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue. Tumour Biol. 2016;37:3807–16.

Article  CAS  PubMed  Google Scholar 

Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008;582:1783–7.

Article  CAS  PubMed  Google Scholar 

Pençe HH, Gündeş E, Senger AS. Prognostic significance of preoperative serum lactate dehydrogenase in patients with resectable gastric adenocarcinoma. Int J Clin Exp Med. 2019;12:2746–52.

Google Scholar